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We report the case of an 85-year-old female patient who suffered from disseminated Nocardia
asteroides infection complicated by a cerebral abscess. Treatment with amikacin for 2 weeks and
ceftriaxone for 6 weeks led to complete recovery, and there was no recurrence of disease over a
follow-up period of 12 months after therapy. The use ofceftriaxone in combination with amika-
cin might significantly shorten the duration of treatment for patients with disseminated nocar-
diosis. This combination of antibiotics merits further investigation with use of a larger sample of
patients.
Sulfonamides or trimethoprim-sulfamethoxazole is given
as standard therapy for disseminated nocardiosis [1-3]. How-
ever, primary resistance to sulfonamides is well known [1,4,
5], late relapses are frequent [4, 6], and prolonged treatment
is often required. Therefore, therapeutic alternatives are
needed. In view of their good in vitro activity against species
of Nocardia. ceftriaxone and cefuroxime seem especially
promising [5, 7]. Amikacin is another drug with excellent
efficacy in vitro [5], in animal models [8], and in treatment of
human disease [4, 9]. Good clinical results have been ob-
served with the synergistic combination of cefuroxime and
amikacin [4].
We report the case of a patient with disseminated nocar-
diosis complicated by cerebral abscess who was successfully
treated with ceftriaxone for 6 weeks and amikacin for 2
weeks.
An 85-year-old female patient was admitted to the hospi-
tal because of arthralgias and multiple skin lesions. On ad-
mission, the patient was afebrile; physical examination re-
vealed multiple nodular reddish lesions on the left thigh and
the lower abdomen that were painful and measured up to
1.5 em.
Laboratory analysis revealed mild leukocytosis (white
blood cell count, 15.1 X 109/L) with 40% neutrophils and a
relative lymphopenia of 10%. The Multi-Merieux skin test
(Institut Merieux, Lyon, France) revealed complete anergy.
Microscopic examination ofpus obtained by puncture ofone
of the cutaneous lesions showed polymorphonuclear leuko-
cytes without bacteria. Over the next 24 hours, further skin
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lesions appeared and signs of peritoneal irritation were ob-
served. A repeated puncture of a cutaneous lesion revealed
delicate, beaded, branching gram-positive filaments. Micro-
scopic examination of the sputum showed the same microor-
ganisms.
A presumptive clinical diagnosis of actinomycosis was
made, and 20 million units of iv penicillin G were adminis-
tered daily. Because of generalized seizures that were as-
sumed to be due to CNS toxicity associated with the use of
penicillin, the treatment was changed to amoxicillin. On day
8 of treatment, a left-sided hemiparesis appeared. The com-
puted tomography (CT) scan revealed a right-sided ring-en-
hancing hemispheric lesion suggestive of an abscess (figure
1). The lumbar puncture showed a normal cell count and a
slightly elevated level of protein (56.8 mg/dL).
In the meantime, culture of a sample obtained by cutane-
ous aspiration revealed N. asteroides that was resistant to tri-
methoprim-sulfamethoxazole and produced penicillinase.
Antibiotic treatment was changed to iv amikacin (MIC, 0.12
JLg/mL) and iv ceftriaxone (MIC, 8 JLg/mL) (for microdilu-
tion method, see [10]). In vitro testing showed that the com-
bination ofceftriaxone and amikacin did not have synergistic
potential. During treatment with amikacin (200 mg b.i.d. iv),
a peak serum concentration of 13.6 mg/L and trough con-
centrations of 2.3-5.5 mg/L were measured.
Ceftriaxone was administered in a total daily dose of 4 g
(divided in two doses). With this treatment, the patient's
neurological deficits were markedly reduced; thus, therapy
with amikacin was stopped after 14 days. Therapy with cef-
triaxone was continued for 6 weeks. After 4 weeks of ther-
apy, a second CT scan showed a marked regression of the
lesion; a third CT scan ofthe brain 2 weeks after termination
of treatment revealed no evidence of a persisting abscess.
Clinically, the patient showed no residual neurological defi-
cits, and the skin changes as well as the signs of peritoneal
irritation had disappeared.
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Figure 1. A CT scan taken at the beginning of antibiotic treat-
ment revealing a right-sided parietal brain abscess with multilocu-
lar ring enhancement and edema.
Disseminated nocardiosis has a poor prognosis, with a mor-
tality rate of 7%-44% [2, II, 12]. Treatment of nocardial
brain abscesses with sulfonamides is usually recommended
for up to I year [2]. Furthermore, since primary resistance
and late relapses occur, alternative regimens are required.
Among the various antibiotics tested, ceftriaxone, cefurox-
ime, and cefotaxime showed good in vitro activity against
Nocardia [5]. Cefuroxime and amikacin have been shown to
kill Nocardia synergistically in vitro [4], thus providing a ra-
tional basis for their clinical use.
In the murine model, cerebral nocardiosis responds better
to amikacin than to trimethoprim-sulfamethoxazole [8].
However, these data should be interpreted with caution: con-
centrations ofthese drugs achieved in the CSF ofhumans are
lower than those achieved in the brains of mice [13-15];
further problems result from the large variability of concen-
trations observed in the CSF ofhumans and the poor correla-
tion between the concentrations measured in CSF and those
in cerebral tissue [14, IS]. Considering that the concentra-
tion of amikacin achieved in the CSF of humans is 10%-15%
of that achieved in serum [12], a CNS effect can be antici-
pated with isolates of Nocardia that require a low MIC for
inhibition; such an effect has been shown in our case, in
which the MIC of amikacin was 0.12 p,g/mL and serum
concentrations of amikacin were between 2.3 mg/L and
13.6 mg/L.
Our patient had an excellent response to therapy with cef-
triaxone and amikacin. The neurological deficits disap-
peared after 3 weeks of treatment, a finding that correlated
with the radiological evidence of regression after 4 weeks of
treatment and the complete normalization of the computed
tomogram 4 weeks later. On the basis of the low MIC (0.12
p,g/mL) ofamikacin and the relatively high MIC of ceftriax-
one (8 p,g/mL) in our case, we assume that amikacin had a
major effect on the CNS manifestation. The possibility of
synergism in vivo cannot be excluded despite its absence in
vitro. The early institution of adequate antibiotic treatment
may have been critical. The use ofcombination therapy with
amikacin and ceftriaxone for patients with disseminated no-
cardiosis merits further investigation.
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